Jazz Pharmaceuticals Valuation Multiples

Jazz Pharmaceuticals Overview

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Founded

2003

HQ

Employees

2.9K

Website

jazzpharmaceuticals.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $4B

EBITDA: $1B

EV

$16B

Valuation Multiples

Multiples.vc

Start free trial

Jazz Pharmaceuticals Financials

Jazz Pharmaceuticals reported last 12-month revenue of $4B and EBITDA of $1B.

In the same LTM period, Jazz Pharmaceuticals generated $4B in gross profit, $1B in EBITDA, and $834M in net income.

Jazz Pharmaceuticals P&L

In the most recent fiscal year, Jazz Pharmaceuticals reported revenue of $4B and EBITDA of $720M.

Jazz Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals has current market cap of $13B, and enterprise value of $16B.

Jazz Pharmaceuticals' stock price is $203.42.

Jazz Pharmaceuticals Valuation Multiples

Jazz Pharmaceuticals trades at 3.6x EV/Revenue multiple, and 14.2x EV/EBITDA.

Jazz Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Jazz Pharmaceuticals has market cap of $13B and EV of $16B.

Equity research analysts estimate Jazz Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Jazz Pharmaceuticals has a P/E ratio of 15.0x.

Jazz Pharmaceuticals Margins & Growth Rates

Jazz Pharmaceuticals' revenue in the last 12 month grew by 5%.

Jazz Pharmaceuticals' revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $1.1M for the same period.

Jazz Pharmaceuticals' rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Jazz Pharmaceuticals' rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Jazz Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Jazz Pharmaceuticals M&A Activity

Jazz Pharmaceuticals acquired XXX companies to date.

Last acquisition by Jazz Pharmaceuticals was on XXXXXXXX, XXXXX. Jazz Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Jazz Pharmaceuticals Investment Activity

Jazz Pharmaceuticals invested in XXX companies to date.

Jazz Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Jazz Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).